Cache Advisors LLC Takes $2.01 Million Position in Eli Lilly and Company (NYSE:LLY)

Cache Advisors LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 2,600 shares of the company’s stock, valued at approximately $2,007,000. Eli Lilly and Company accounts for 0.8% of Cache Advisors LLC’s investment portfolio, making the stock its 29th largest position.

A number of other institutional investors have also recently bought and sold shares of LLY. GF Fund Management CO. LTD. acquired a new position in Eli Lilly and Company in the 4th quarter worth approximately $25,804,000. CTC Alternative Strategies Ltd. lifted its holdings in shares of Eli Lilly and Company by 107.7% in the fourth quarter. CTC Alternative Strategies Ltd. now owns 1,300 shares of the company’s stock valued at $1,004,000 after purchasing an additional 674 shares in the last quarter. Pinney & Scofield Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $5,694,000. Parr Mcknight Wealth Management Group LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at $4,719,000. Finally, Public Employees Retirement System of Ohio grew its holdings in shares of Eli Lilly and Company by 19.8% during the fourth quarter. Public Employees Retirement System of Ohio now owns 479,489 shares of the company’s stock valued at $370,166,000 after buying an additional 79,176 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Citigroup reduced their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,011.37.

Eli Lilly and Company Stock Performance

LLY opened at $713.99 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a market cap of $676.67 billion, a PE ratio of 60.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The stock has a 50-day moving average of $789.29 and a 200-day moving average of $803.00. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the firm posted $2.58 earnings per share. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.84%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.